Chris Plummer

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 717 citations · Full text

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

Anna Jones, Malcolm Barlow, Peter Barrett‐Lee et al. · British Journal of Cancer · 2009 · 215 citations · Full text

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer

Sarah Halford, Gareth J. Veal, Stephen R. Wedge et al. · Clinical Cancer Research · 2023 · 177 citations · Full text

CRT Survey II: A European Society of Cardiology Survey of Cardiac Resynchronisation Therapy in 11 088 Patients—Who is doing what to whom and How?

Kenneth Dickstein, Camilla Normand, Angelo Auricchio et al. · European Journal of Heart Failure · 2018 · 125 citations · Full text